Orphan drug hearing
Executive Summary
Sen. Metzenbaum (D-Ohio) has scheduled an oversight hearing on high-priced, highly profitable orphan drugs before his Senate Judiciary/Antitrust Subcommittee for Jan. 21. Genentech, Amgen and Fujisawa are expected to be among the witnesses. Metzenbaum has asked that Sen. Kennedy (D-Mass.) subsequently schedule a legislative hearing before the Labor & Human Resources Committee on orphan drug amendments (S 2060), sponsored by Metzenbaum and Sen. Kassebaum (R-Kan.).